Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
admin 13th March 2018 Uncategorised 0Amgen lost its bid to prevent generic competition to its blockbuster thyroid drug Sensipar. Then, to add insult to injury, its rivals in the PCSK9 cholesterol-lowering market, Sanofi and Regeneron, rolled out trial data that put Amgen’s Repatha at risk of losing market share. Now what?
More: Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Source: fierce